2020 Interstitial Cystitis (Painful Bladder Syndrome) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Interstitial Cystitis (Painful Bladder Syndrome) pipeline report presents a comprehensive overview of the research and development of Interstitial Cystitis (Painful Bladder Syndrome) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, six drugs in Pre-clinical phase, five drugs in Phase 2, and two drugs in Phase 3
As of February 2020, the Interstitial Cystitis (Painful Bladder Syndrome) pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Interstitial Cystitis (Painful Bladder Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell membrane permeability inhibitors; Mitogen-activated protein kinase 8 inhibitors; Nociceptin receptor agonists; PAR-1 antagonist; Purinergic P2X3 receptor antagonists; SNAP-25 inhibitor; Sodium channel antagonists; Thrombin inhibitors; Tumor Necrosis Factor Alpha (TNF-a) Inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Interstitial Cystitis (Painful Bladder Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Interstitial Cystitis (Painful Bladder Syndrome) pipeline drugs profiled in the report include- ALV-107, GM-0111, GRT6010, 32264, KRP-116D (dimethyl sulfoxide), LP-08, Botulinum toxin A , BLU-5937 (NEO-5937), F 16357, certolizumab pegol, URG101 (heparin and lidocaine), URG501 (pentosan polysulfate), URG 801, XG-102 (brimapitide), SI-722
As of February 2020, the Interstitial Cystitis (Painful Bladder Syndrome) pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Interstitial Cystitis (Painful Bladder Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell membrane permeability inhibitors; Mitogen-activated protein kinase 8 inhibitors; Nociceptin receptor agonists; PAR-1 antagonist; Purinergic P2X3 receptor antagonists; SNAP-25 inhibitor; Sodium channel antagonists; Thrombin inhibitors; Tumor Necrosis Factor Alpha (TNF-a) Inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Interstitial Cystitis (Painful Bladder Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Interstitial Cystitis (Painful Bladder Syndrome) development
- Interstitial Cystitis (Painful Bladder Syndrome) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Interstitial Cystitis (Painful Bladder Syndrome) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Interstitial Cystitis (Painful Bladder Syndrome) pipeline candidates included
- Business overview and snapshot of all companies involved in Interstitial Cystitis (Painful Bladder Syndrome) pipeline are included
- Latest market and pipeline developments are provided in the report
Interstitial Cystitis (Painful Bladder Syndrome) pipeline drugs profiled in the report include- ALV-107, GM-0111, GRT6010, 32264, KRP-116D (dimethyl sulfoxide), LP-08, Botulinum toxin A , BLU-5937 (NEO-5937), F 16357, certolizumab pegol, URG101 (heparin and lidocaine), URG501 (pentosan polysulfate), URG 801, XG-102 (brimapitide), SI-722
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Interstitial Cystitis (Painful Bladder Syndrome) Condition
2.3 Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Snapshot, 2020
2.4 Companies investing in Interstitial Cystitis (Painful Bladder Syndrome) pipeline therapeutics
2.5 Phase wise Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Products
2.7 Route of Administration of Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Alivio Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 BELLUS Health Inc Overview, Contacts and ASD Pipeline Drugs
3.3 GlycoMira Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.5 Harrow Health Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Lipella Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Pierre Fabre Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Seikagaku Corporation Overview, Contacts and ASD Pipeline Drugs
3.10 UCB SA Overview, Contacts and ASD Pipeline Drugs
3.11 Urigen Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Xigen SA Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ALV-107 Drug Details
4.1.1 ALV-107 Current Status
4.1.2 ALV-107 Drug Overview
4.1.3 ALV-107 Mechanism of Action
4.1.4 ALV-107 Licensing/Collaboration Companies
4.1.5 ALV-107 Clinical Trials
4.2 GM-0111 Drug Details
4.2.1 GM-0111 Current Status
4.2.2 GM-0111 Drug Overview
4.2.3 GM-0111 Mechanism of Action
4.2.4 GM-0111 Licensing/Collaboration Companies
4.2.5 GM-0111 Clinical Trials
4.3 GRT6010 Drug Details
4.3.1 GRT6010 Current Status
4.3.2 GRT6010 Drug Overview
4.3.3 GRT6010 Mechanism of Action
4.3.4 GRT6010 Licensing/Collaboration Companies
4.3.5 GRT6010 Clinical Trials
4.4 32264 Drug Details
4.4.1 32264 Current Status
4.4.2 32264 Drug Overview
4.4.3 32264 Mechanism of Action
4.4.4 32264 Licensing/Collaboration Companies
4.4.5 32264 Clinical Trials
4.5 KRP-116D (dimethyl sulfoxide) Drug Details
4.5.1 KRP-116D (dimethyl sulfoxide) Current Status
4.5.2 KRP-116D (dimethyl sulfoxide) Drug Overview
4.5.3 KRP-116D (dimethyl sulfoxide) Mechanism of Action
4.5.4 KRP-116D (dimethyl sulfoxide) Licensing/Collaboration Companies
4.5.5 KRP-116D (dimethyl sulfoxide) Clinical Trials
4.6 LP-08 Drug Details
4.6.1 LP-08 Current Status
4.6.2 LP-08 Drug Overview
4.6.3 LP-08 Mechanism of Action
4.6.4 LP-08 Licensing/Collaboration Companies
4.6.5 LP-08 Clinical Trials
4.7 Botulinum toxin A Drug Details
4.7.1 Botulinum toxin A Current Status
4.7.2 Botulinum toxin A Drug Overview
4.7.3 Botulinum toxin A Mechanism of Action
4.7.4 Botulinum toxin A Licensing/Collaboration Companies
4.7.5 Botulinum toxin A Clinical Trials
4.8 BLU-5937 (NEO-5937) Drug Details
4.8.1 BLU-5937 (NEO-5937) Current Status
4.8.2 BLU-5937 (NEO-5937) Drug Overview
4.8.3 BLU-5937 (NEO-5937) Mechanism of Action
4.8.4 BLU-5937 (NEO-5937) Licensing/Collaboration Companies
4.8.5 BLU-5937 (NEO-5937) Clinical Trials
4.9 F 16357 Drug Details
4.9.1 F 16357 Current Status
4.9.2 F 16357 Drug Overview
4.9.3 F 16357 Mechanism of Action
4.9.4 F 16357 Licensing/Collaboration Companies
4.9.5 F 16357 Clinical Trials
4.10 certolizumab pegol Drug Details
4.10.1 certolizumab pegol Current Status
4.10.2 certolizumab pegol Drug Overview
4.10.3 certolizumab pegol Mechanism of Action
4.10.4 certolizumab pegol Licensing/Collaboration Companies
4.10.5 certolizumab pegol Clinical Trials
4.11 URG101 (heparin and lidocaine) Drug Details
4.11.1 URG101 (heparin and lidocaine) Current Status
4.11.2 URG101 (heparin and lidocaine) Drug Overview
4.11.3 URG101 (heparin and lidocaine) Mechanism of Action
4.11.4 URG101 (heparin and lidocaine) Licensing/Collaboration Companies
4.11.5 URG101 (heparin and lidocaine) Clinical Trials
4.12 URG501 (pentosan polysulfate) Drug Details
4.12.1 URG501 (pentosan polysulfate) Current Status
4.12.2 URG501 (pentosan polysulfate) Drug Overview
4.12.3 URG501 (pentosan polysulfate) Mechanism of Action
4.12.4 URG501 (pentosan polysulfate) Licensing/Collaboration Companies
4.12.5 URG501 (pentosan polysulfate) Clinical Trials
4.13 URG 801 Drug Details
4.13.1 URG 801 Current Status
4.13.2 URG 801 Drug Overview
4.13.3 URG 801 Mechanism of Action
4.13.4 URG 801 Licensing/Collaboration Companies
4.13.5 URG 801 Clinical Trials
4.14 XG-102 (brimapitide) Drug Details
4.14.1 XG-102 (brimapitide) Current Status
4.14.2 XG-102 (brimapitide) Drug Overview
4.14.3 XG-102 (brimapitide) Mechanism of Action
4.14.4 XG-102 (brimapitide) Licensing/Collaboration Companies
4.14.5 XG-102 (brimapitide) Clinical Trials
4.15 SI-722 Drug Details
4.15.1 SI-722 Current Status
4.15.2 SI-722 Drug Overview
4.15.3 SI-722 Mechanism of Action
4.15.4 SI-722 Licensing/Collaboration Companies
4.15.5 SI-722 Clinical Trials
5. LATEST INTERSTITIAL CYSTITIS (PAINFUL BLADDER SYNDROME) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Interstitial Cystitis (Painful Bladder Syndrome) Condition
2.3 Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Snapshot, 2020
2.4 Companies investing in Interstitial Cystitis (Painful Bladder Syndrome) pipeline therapeutics
2.5 Phase wise Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Products
2.7 Route of Administration of Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Alivio Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 BELLUS Health Inc Overview, Contacts and ASD Pipeline Drugs
3.3 GlycoMira Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.5 Harrow Health Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Lipella Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Pierre Fabre Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Seikagaku Corporation Overview, Contacts and ASD Pipeline Drugs
3.10 UCB SA Overview, Contacts and ASD Pipeline Drugs
3.11 Urigen Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Xigen SA Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ALV-107 Drug Details
4.1.1 ALV-107 Current Status
4.1.2 ALV-107 Drug Overview
4.1.3 ALV-107 Mechanism of Action
4.1.4 ALV-107 Licensing/Collaboration Companies
4.1.5 ALV-107 Clinical Trials
4.2 GM-0111 Drug Details
4.2.1 GM-0111 Current Status
4.2.2 GM-0111 Drug Overview
4.2.3 GM-0111 Mechanism of Action
4.2.4 GM-0111 Licensing/Collaboration Companies
4.2.5 GM-0111 Clinical Trials
4.3 GRT6010 Drug Details
4.3.1 GRT6010 Current Status
4.3.2 GRT6010 Drug Overview
4.3.3 GRT6010 Mechanism of Action
4.3.4 GRT6010 Licensing/Collaboration Companies
4.3.5 GRT6010 Clinical Trials
4.4 32264 Drug Details
4.4.1 32264 Current Status
4.4.2 32264 Drug Overview
4.4.3 32264 Mechanism of Action
4.4.4 32264 Licensing/Collaboration Companies
4.4.5 32264 Clinical Trials
4.5 KRP-116D (dimethyl sulfoxide) Drug Details
4.5.1 KRP-116D (dimethyl sulfoxide) Current Status
4.5.2 KRP-116D (dimethyl sulfoxide) Drug Overview
4.5.3 KRP-116D (dimethyl sulfoxide) Mechanism of Action
4.5.4 KRP-116D (dimethyl sulfoxide) Licensing/Collaboration Companies
4.5.5 KRP-116D (dimethyl sulfoxide) Clinical Trials
4.6 LP-08 Drug Details
4.6.1 LP-08 Current Status
4.6.2 LP-08 Drug Overview
4.6.3 LP-08 Mechanism of Action
4.6.4 LP-08 Licensing/Collaboration Companies
4.6.5 LP-08 Clinical Trials
4.7 Botulinum toxin A Drug Details
4.7.1 Botulinum toxin A Current Status
4.7.2 Botulinum toxin A Drug Overview
4.7.3 Botulinum toxin A Mechanism of Action
4.7.4 Botulinum toxin A Licensing/Collaboration Companies
4.7.5 Botulinum toxin A Clinical Trials
4.8 BLU-5937 (NEO-5937) Drug Details
4.8.1 BLU-5937 (NEO-5937) Current Status
4.8.2 BLU-5937 (NEO-5937) Drug Overview
4.8.3 BLU-5937 (NEO-5937) Mechanism of Action
4.8.4 BLU-5937 (NEO-5937) Licensing/Collaboration Companies
4.8.5 BLU-5937 (NEO-5937) Clinical Trials
4.9 F 16357 Drug Details
4.9.1 F 16357 Current Status
4.9.2 F 16357 Drug Overview
4.9.3 F 16357 Mechanism of Action
4.9.4 F 16357 Licensing/Collaboration Companies
4.9.5 F 16357 Clinical Trials
4.10 certolizumab pegol Drug Details
4.10.1 certolizumab pegol Current Status
4.10.2 certolizumab pegol Drug Overview
4.10.3 certolizumab pegol Mechanism of Action
4.10.4 certolizumab pegol Licensing/Collaboration Companies
4.10.5 certolizumab pegol Clinical Trials
4.11 URG101 (heparin and lidocaine) Drug Details
4.11.1 URG101 (heparin and lidocaine) Current Status
4.11.2 URG101 (heparin and lidocaine) Drug Overview
4.11.3 URG101 (heparin and lidocaine) Mechanism of Action
4.11.4 URG101 (heparin and lidocaine) Licensing/Collaboration Companies
4.11.5 URG101 (heparin and lidocaine) Clinical Trials
4.12 URG501 (pentosan polysulfate) Drug Details
4.12.1 URG501 (pentosan polysulfate) Current Status
4.12.2 URG501 (pentosan polysulfate) Drug Overview
4.12.3 URG501 (pentosan polysulfate) Mechanism of Action
4.12.4 URG501 (pentosan polysulfate) Licensing/Collaboration Companies
4.12.5 URG501 (pentosan polysulfate) Clinical Trials
4.13 URG 801 Drug Details
4.13.1 URG 801 Current Status
4.13.2 URG 801 Drug Overview
4.13.3 URG 801 Mechanism of Action
4.13.4 URG 801 Licensing/Collaboration Companies
4.13.5 URG 801 Clinical Trials
4.14 XG-102 (brimapitide) Drug Details
4.14.1 XG-102 (brimapitide) Current Status
4.14.2 XG-102 (brimapitide) Drug Overview
4.14.3 XG-102 (brimapitide) Mechanism of Action
4.14.4 XG-102 (brimapitide) Licensing/Collaboration Companies
4.14.5 XG-102 (brimapitide) Clinical Trials
4.15 SI-722 Drug Details
4.15.1 SI-722 Current Status
4.15.2 SI-722 Drug Overview
4.15.3 SI-722 Mechanism of Action
4.15.4 SI-722 Licensing/Collaboration Companies
4.15.5 SI-722 Clinical Trials
5. LATEST INTERSTITIAL CYSTITIS (PAINFUL BLADDER SYNDROME) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
